ImmuCell to delay resubmission of FDA application for Re-Tain

ICCC Stock  USD 4.89  0.10  2.00%   
About 61% of ImmuCell's investor base is looking to short. The analysis of the overall investor sentiment regarding ImmuCell suggests that many traders are alarmed. The current market sentiment, together with ImmuCell's historical and current headlines, can help investors time the market. In addition, many technical investors use ImmuCell stock news signals to limit their universe of possible portfolio assets.
  
ImmuCell said it is delaying resubmission of its market application to the US Food and Drug Administration for its dairy cattle medication Re-Tain by one month. Read more here.

Read at seekingalpha.com
seekingalpha News
  

ImmuCell Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards ImmuCell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ImmuCell Fundamental Analysis

We analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

ImmuCell is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

ImmuCell Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmuCell stock to make a market-neutral strategy. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics with similar companies.

Peers

ImmuCell Related Equities

PTIXProtagenic Therapeutics   5.77   
0%
100.0%
CVKDCadrenal Therapeutics,   4.55   
0%
78.0%
FENCFennec Pharmaceuticals   1.32   
0%
22.0%
HCWBHCW Biologics   0.75   
0%
12.0%
ANEBAnebulo Pharmaceuticals   0.64   
0%
11.0%
ACOGFAlpha Cognition   0.35   
0%
6.0%
TRGNFTransgene   0.00   
0%
0%
XOMAOXOMA   0.39   
6.0%
0%
LCTXLineage Cell   0.43   
7.0%
0%
TPSTTempest Therapeutics   0.45   
7.0%
0%
LIPOLipella Pharmaceuticals   1.32   
22.0%
0%
RZLTRezolute   1.39   
24.0%
0%
MNOVMediciNova   1.74   
30.0%
0%
ELYMEliem Therapeutics   1.90   
32.0%
0%
ONTTFOxford Nanopore   4.88   
84.0%
0%

Complementary Tools for ImmuCell Stock analysis

When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges